China To Probe Prices Of 60 Foreign, Domestic Drug Manufacturers
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline, Merck and Boehringer Ingelheim are among manufacturers operating in China that are about to have their prices reviewed by the National Development and Reform Commission in an expansion of its current antitrust probe involving foreign-made baby food.